PODD up +1.16% percent Today $PODD High is at 45.8
Post# of 45
Posted On: 11/11/2014 3:43:18 PM
PODD up +1.16% percent Today $PODD High is at 45.88 and the Low 44.42 with current volume of 225,625.
Recent News posted below.
Insulet Corp PODD other info.
http://investorshangout.com/Insulet-Corp-PODD-55144/
PODD Insulet Corp Recent Headline News
Uptrend Call Working As Insulet Stock Rises 10.9% (PODD)
Comtex SmarTrend(R) - Fri Nov 07, 9:59AM CST
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on September 24th, 2014 at $37.83. In approximately 1 month, Insulet has returned 10.86% as of today's recent price of $41.94.
PODD: 45.40 (+0.65)
Insulet's (PODD) CEO Patrick Sullivan on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 9:41PM CST
PODD: 45.40 (+0.65)
Insulet tops 3Q profit forecasts
Automated Insights - Wed Nov 05, 4:27PM CST
BEDFORD, Mass. (AP) _ Insulet Corp. (PODD) on Wednesday reported a loss of $10.8 million in its third quarter.
PODD: 45.40 (+0.65)
Insulet misses by $0.18, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:13PM CST
PODD: 45.40 (+0.65)
Insulet (PODD) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST
PODD: 45.40 (+0.65)
Insulet Corporation Appoints New Chief Financial Officer and Executive Vice President, Human Resources
Marketwired - Wed Nov 05, 3:08PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the promotion of Allison Dorval to Chief Financial Officer effective November 6, 2014 and Brad Thomas as Executive Vice President, Human Resources and Organizational Development, effective immediately.
PODD: 45.40 (+0.65)
Insulet Reports Third Quarter 2014 Results
Marketwired - Wed Nov 05, 3:08PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced financial results for the three and nine months ended September 30, 2014.
PODD: 45.40 (+0.65)
Insulet Corporation to Present at Upcoming Investor Conferences
Marketwired - Mon Nov 03, 3:15PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, plans to participate in the following upcoming investor conferences:
PODD: 45.40 (+0.65)
Insulet Shares Up 14.4% Since SmarTrend's Buy Recommendation (PODD)
Comtex SmarTrend(R) - Fri Oct 31, 9:34AM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ ODD) on September 24th, 2014 at $37.83. In approximately 1 month, Insulet has returned 14.43% as of today's recent price of $43.29.
PODD: 45.40 (+0.65)
Insulet Corporation to Report Third Quarter 2014 Financial Results on November 5, 2014
Marketwired - Tue Oct 21, 3:15PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, plans to release its financial results for the third quarter of 2014 on November 5, 2014 after the close of the financial markets.
PODD: 45.40 (+0.65)
5 Breakout Trades That Are Beating the Market's Slump
at The Street - Tue Oct 14, 10:03AM CDT
As Mr. Market kicks off another correction week, we're focusing on five stocks that look primed to move higher.
PODD: 45.40 (+0.65), CHSP: 33.61 (-0.08), VAC: 72.00 (+0.76), ITC: 40.55 (+0.10), EXR: 58.45 (-0.20)
Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation
GlobeNewswire - Thu Oct 09, 7:23AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it plans to develop a clinical program using Cenderitide for the treatment of post-acute heart failure using Insulet's drug delivery system based on the OmniPodinsulin management system.
PODD: 45.40 (+0.65)
US Diabetes Monitoring, Treatment and Drug Delivery Market 2014-2020
M2 - Tue Sep 30, 9:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/45xv4l/us_diabetes) has announced the addition of the "US Diabetes Monitoring, Treatment and Drug Delivery Market - 2014" report to their offering. The diabetes monitoring, treatment and drug delivery market is segmented into eight categories. Among these, growing segments included the continuous glucose monitoring (CGM), insulin pump and supplies, modern insulin, insulin pens and pen needle markets. These segments have one aspect in common: they are newer ways of treating diabetes. CGM and pump technologies are improving at a fast pace toward full integration and automatic insulin suspension. Modern insulin is rapidly replacing human insulin due to its superior qualities. Insulin pens are replacing insulin syringes because they are discreet, more accurate and require less time. These segments will drive the overall market up through 2020. Report Highlights: - Includes additional information on reimbursement changes - Includes new segmentation for the test strip market - Includes new segment and segmentation on: - Pen needles - Reusable pens - Prefilled pens - Pen cartridges - Information on the first step towards an artificial pancreas technology: - Its effects on the CGM market - Its effects on the pump market - Detailed analysis of the modern insulin market in the U.S. - Rapid-acting modern insulin - Long-acting modern insulin - Premixed modern insulin - Market projections for test strips and meters given the changes in reimbursement - The decline rate in insulin syringes Key Topics Covered: 1. Executive Summary 2. Research Methodology 3. U.S. Diabetes Diagnosis, Treatment And Drug Delivery Market 4. Traditional Blood Glucose Meter Market 5. Traditional Blood Glucose Test Strip Market 6. Lancet And Lancing Device Market 7. Continuous Glucose Monitoring Market 8. Insulin Pump Market 9. Modern Insulin Market 10. Insulin Syringe Market 11. Modern Insulin Pen Market 12. Abbreviations Companies Mentioned - Abbott - Animas - Bayer - Becton Dickinson - Covidien - Dexcom - Eli Lilly - Insulet Corporation - Lifescan - Medtronic - Nipro Diagnostics - Nova Biomedical - Novo Nordisk - Owen Mumford - Roche - Sanofi - Valeritas For more information visit http://www.researchandmarkets.com/research/45...s_diabetes
PODD: 45.40 (+0.65), NVO: 44.28 (+0.98), MDT: 68.86 (+0.15), LLY: 67.91 (-0.44)
Nasdaq stocks posting largest percentage increases
AP - Thu Sep 18, 12:18PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
AMBA: 48.75 (-0.46), PRSC: 37.62 (-0.26), PERI: 5.90 (+0.08), RJET: 12.98 (-0.11), MSON: 11.84 (+0.29), QDEL: 28.29 (+0.27), ISRL: 142.00 (+0.60), TGTX: 12.85 (+0.30), RENT: 77.57 (-3.36), NYNY: 7.47 (-0.31), YRCW: 24.40 (+0.10), EMKR: 5.26 (+0.08), PODD: 45.40 (+0.65), AUXL: 32.60 (-0.10), APOG: 44.94 (+0.52), IDSY: 6.58 (+0.18)
Insulet hires Patrick J. Sullivan as president, CEO and director
M2 - Wed Sep 17, 7:13AM CDT
Insulin pump technology company Insulet (NASDAQ ODD) reported on Tuesday the appointment of Patrick J. Sullivan as its president, chief executive officer and director.
PODD: 45.40 (+0.65)
Insulet Corporation Appoints Patrick J. Sullivan as President and Chief Executive Officer
Marketwire - Tue Sep 16, 3:30PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced that Patrick J. Sullivan has been appointed President and Chief Executive Officer, and Director effective immediately. Mr. Sullivan succeeds Duane DeSisto, who is retiring after 13 years at the Company. Mr. DeSisto will be available to the Company as a consultant through the end of 2014 to assist with an effective leadership transition.
PODD: 45.40 (+0.65), PKI: 43.92 (-0.10), HOLX: 26.52 (-0.03)
Insulet Shares Down 13.1% Since SmarTrend's Sell Call (PODD)
Comtex SmarTrend(R) - Tue Sep 16, 9:16AM CDT
SmarTrend identified a Downtrend for Insulet (NASDAQ ODD) on July 17th, 2014 at $36.87. In approximately 2 months, Insulet has returned 13.07% as of today's recent price of $32.05.
PODD: 45.40 (+0.65)
Insulet Corporation to Present at the Morgan Stanley Global Healthcare Conference
Marketwire - Tue Sep 02, 3:05PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the Company will participate in the Morgan Stanley Global Healthcare Conference at the Grand Hyatt New York. Management is scheduled to present an overview of the Company on Tuesday, September 9, 2014 at 1:30 p.m. ET.
PODD: 45.40 (+0.65), MS: 35.79 (-0.09)
Insulet elects Timothy J. Scannell to board
M2 - Mon Aug 18, 7:30AM CDT
Insulin pump technology company Insulet (NASDAQ ODD) disclosed on Friday the addition of Timothy J. Scannell to its board of directors.
PODD: 45.40 (+0.65)
Insulet Appoints Timothy J. Scannell to Board of Directors
Marketwire - Fri Aug 15, 3:30PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the appointment of Timothy J. Scannell to the Company's board of directors. A seasoned senior medical device executive, Mr. Scannell currently serves as Group President, MedSurg & Neurotechnology at Stryker Corporation.
PODD: 45.40 (+0.65)
Recent News posted below.
Insulet Corp PODD other info.
http://investorshangout.com/Insulet-Corp-PODD-55144/
PODD Insulet Corp Recent Headline News
Uptrend Call Working As Insulet Stock Rises 10.9% (PODD)
Comtex SmarTrend(R) - Fri Nov 07, 9:59AM CST
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on September 24th, 2014 at $37.83. In approximately 1 month, Insulet has returned 10.86% as of today's recent price of $41.94. PODD: 45.40 (+0.65)
Insulet's (PODD) CEO Patrick Sullivan on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 9:41PM CST
PODD: 45.40 (+0.65)
Insulet tops 3Q profit forecasts
Automated Insights - Wed Nov 05, 4:27PM CST
BEDFORD, Mass. (AP) _ Insulet Corp. (PODD) on Wednesday reported a loss of $10.8 million in its third quarter.
PODD: 45.40 (+0.65)
Insulet misses by $0.18, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:13PM CST
PODD: 45.40 (+0.65)
Insulet (PODD) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST
PODD: 45.40 (+0.65)
Insulet Corporation Appoints New Chief Financial Officer and Executive Vice President, Human Resources
Marketwired - Wed Nov 05, 3:08PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the promotion of Allison Dorval to Chief Financial Officer effective November 6, 2014 and Brad Thomas as Executive Vice President, Human Resources and Organizational Development, effective immediately.
PODD: 45.40 (+0.65)
Insulet Reports Third Quarter 2014 Results
Marketwired - Wed Nov 05, 3:08PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced financial results for the three and nine months ended September 30, 2014.
PODD: 45.40 (+0.65)
Insulet Corporation to Present at Upcoming Investor Conferences
Marketwired - Mon Nov 03, 3:15PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, plans to participate in the following upcoming investor conferences:
PODD: 45.40 (+0.65)
Insulet Shares Up 14.4% Since SmarTrend's Buy Recommendation (PODD)
Comtex SmarTrend(R) - Fri Oct 31, 9:34AM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on September 24th, 2014 at $37.83. In approximately 1 month, Insulet has returned 14.43% as of today's recent price of $43.29. PODD: 45.40 (+0.65)
Insulet Corporation to Report Third Quarter 2014 Financial Results on November 5, 2014
Marketwired - Tue Oct 21, 3:15PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, plans to release its financial results for the third quarter of 2014 on November 5, 2014 after the close of the financial markets.
PODD: 45.40 (+0.65)
5 Breakout Trades That Are Beating the Market's Slump
at The Street - Tue Oct 14, 10:03AM CDT
As Mr. Market kicks off another correction week, we're focusing on five stocks that look primed to move higher.
PODD: 45.40 (+0.65), CHSP: 33.61 (-0.08), VAC: 72.00 (+0.76), ITC: 40.55 (+0.10), EXR: 58.45 (-0.20)
Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation
GlobeNewswire - Thu Oct 09, 7:23AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it plans to develop a clinical program using Cenderitide for the treatment of post-acute heart failure using Insulet's drug delivery system based on the OmniPodinsulin management system.
PODD: 45.40 (+0.65)
US Diabetes Monitoring, Treatment and Drug Delivery Market 2014-2020
M2 - Tue Sep 30, 9:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/45xv4l/us_diabetes) has announced the addition of the "US Diabetes Monitoring, Treatment and Drug Delivery Market - 2014" report to their offering. The diabetes monitoring, treatment and drug delivery market is segmented into eight categories. Among these, growing segments included the continuous glucose monitoring (CGM), insulin pump and supplies, modern insulin, insulin pens and pen needle markets. These segments have one aspect in common: they are newer ways of treating diabetes. CGM and pump technologies are improving at a fast pace toward full integration and automatic insulin suspension. Modern insulin is rapidly replacing human insulin due to its superior qualities. Insulin pens are replacing insulin syringes because they are discreet, more accurate and require less time. These segments will drive the overall market up through 2020. Report Highlights: - Includes additional information on reimbursement changes - Includes new segmentation for the test strip market - Includes new segment and segmentation on: - Pen needles - Reusable pens - Prefilled pens - Pen cartridges - Information on the first step towards an artificial pancreas technology: - Its effects on the CGM market - Its effects on the pump market - Detailed analysis of the modern insulin market in the U.S. - Rapid-acting modern insulin - Long-acting modern insulin - Premixed modern insulin - Market projections for test strips and meters given the changes in reimbursement - The decline rate in insulin syringes Key Topics Covered: 1. Executive Summary 2. Research Methodology 3. U.S. Diabetes Diagnosis, Treatment And Drug Delivery Market 4. Traditional Blood Glucose Meter Market 5. Traditional Blood Glucose Test Strip Market 6. Lancet And Lancing Device Market 7. Continuous Glucose Monitoring Market 8. Insulin Pump Market 9. Modern Insulin Market 10. Insulin Syringe Market 11. Modern Insulin Pen Market 12. Abbreviations Companies Mentioned - Abbott - Animas - Bayer - Becton Dickinson - Covidien - Dexcom - Eli Lilly - Insulet Corporation - Lifescan - Medtronic - Nipro Diagnostics - Nova Biomedical - Novo Nordisk - Owen Mumford - Roche - Sanofi - Valeritas For more information visit http://www.researchandmarkets.com/research/45...s_diabetes
PODD: 45.40 (+0.65), NVO: 44.28 (+0.98), MDT: 68.86 (+0.15), LLY: 67.91 (-0.44)
Nasdaq stocks posting largest percentage increases
AP - Thu Sep 18, 12:18PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
AMBA: 48.75 (-0.46), PRSC: 37.62 (-0.26), PERI: 5.90 (+0.08), RJET: 12.98 (-0.11), MSON: 11.84 (+0.29), QDEL: 28.29 (+0.27), ISRL: 142.00 (+0.60), TGTX: 12.85 (+0.30), RENT: 77.57 (-3.36), NYNY: 7.47 (-0.31), YRCW: 24.40 (+0.10), EMKR: 5.26 (+0.08), PODD: 45.40 (+0.65), AUXL: 32.60 (-0.10), APOG: 44.94 (+0.52), IDSY: 6.58 (+0.18)
Insulet hires Patrick J. Sullivan as president, CEO and director
M2 - Wed Sep 17, 7:13AM CDT
Insulin pump technology company Insulet (NASDAQ
ODD) reported on Tuesday the appointment of Patrick J. Sullivan as its president, chief executive officer and director. PODD: 45.40 (+0.65)
Insulet Corporation Appoints Patrick J. Sullivan as President and Chief Executive Officer
Marketwire - Tue Sep 16, 3:30PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced that Patrick J. Sullivan has been appointed President and Chief Executive Officer, and Director effective immediately. Mr. Sullivan succeeds Duane DeSisto, who is retiring after 13 years at the Company. Mr. DeSisto will be available to the Company as a consultant through the end of 2014 to assist with an effective leadership transition.
PODD: 45.40 (+0.65), PKI: 43.92 (-0.10), HOLX: 26.52 (-0.03)
Insulet Shares Down 13.1% Since SmarTrend's Sell Call (PODD)
Comtex SmarTrend(R) - Tue Sep 16, 9:16AM CDT
SmarTrend identified a Downtrend for Insulet (NASDAQ
ODD) on July 17th, 2014 at $36.87. In approximately 2 months, Insulet has returned 13.07% as of today's recent price of $32.05. PODD: 45.40 (+0.65)
Insulet Corporation to Present at the Morgan Stanley Global Healthcare Conference
Marketwire - Tue Sep 02, 3:05PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the Company will participate in the Morgan Stanley Global Healthcare Conference at the Grand Hyatt New York. Management is scheduled to present an overview of the Company on Tuesday, September 9, 2014 at 1:30 p.m. ET.
PODD: 45.40 (+0.65), MS: 35.79 (-0.09)
Insulet elects Timothy J. Scannell to board
M2 - Mon Aug 18, 7:30AM CDT
Insulin pump technology company Insulet (NASDAQ
ODD) disclosed on Friday the addition of Timothy J. Scannell to its board of directors. PODD: 45.40 (+0.65)
Insulet Appoints Timothy J. Scannell to Board of Directors
Marketwire - Fri Aug 15, 3:30PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the appointment of Timothy J. Scannell to the Company's board of directors. A seasoned senior medical device executive, Mr. Scannell currently serves as Group President, MedSurg & Neurotechnology at Stryker Corporation.
PODD: 45.40 (+0.65)
(0)
(0)Insulet Corp. (PODD) Stock Research Links
Scroll down for more posts ▼